Abstract
The liver glycogen storage disorders (GSDs) comprise GSD I, the hepatic presentations of GSD III, GSD IV, GSD VI, the liver forms of GSD IX, and GSD 0. GSD I, III, VI, and IX present similarly with hypoglycemia, marked hepatomegaly, and growth retardation. GSD I is the most severe affecting both glycogen breakdown and gluconeogenesis. In GSD Ib there is additionally a disorder of neutrophil function. Most patients with GSD III have a syndrome that includes hepatopathy, myopathy, and often cardiomyo pathy. GSD VI and GSD IX are the least severe: there is only a mild tendency to fasting hypoglycemia, liver size normalises with age, and patients reach normal adult height. GSD IV manifests in most patients in infancy or childhood as hepatic failure with cirrhosis leading to end-stage liver disease. GSD 0 presents in infancy or early childhood with fasting hypoglycemia and ketosis and, in contrast, with postprandial hyperglycemia and hyperlactatemia. Treatment is primarily dietary and aims to prevent hypoglycemia and suppress secondary metabolic decompensation. This usually requires frequent feeds by day, and in GSD I and in some patients with GSD III, continuous nocturnal gastric feeding.
The muscle glycogenoses fall into two clinical groups. The first comprises GSD V, GSD VII, the muscle forms of GSD IX (VIII according to McKusick), phosphoglycerate kinase deficiency (IX according to McKusick), GSD X, GSD XI, GSD XII and GSD XIII, and is characterised by exercise intolerance with exercise-induced myalgia and cramps, which are often followed by rhabdomyolysis and myoglobinuria; all symptoms are reversible with rest. Disorders in the second group, consisting of the myopathic form of GSD III, and rare neuromuscular forms of GSD IV, manifest as sub-acute or chronic myopathies, with weakness of trunk, limb, and respiratory muscles. Involvement of other organs (erythrocytes, central or peripheral nervous system, heart, liver) is possible, as most of these enzymes defects are not confined to skeletal muscle.
Generalized glycogenoses comprise GSD II, caused by the deficiency of a lysosomal enzyme, and Danon disease due to the deficiency of a lysosomal membrane protein. Recent work on myoclonus epilepsy with Lafora bodies (Lafora disease) suggests that this is a glycogenosis, probably due to abnormal glycogen synthesis. GSD II can be treated by enzyme replacement therapy, but there is no specific treatment for Danon and Lafora disease.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Rake JP, Visser G, Labrune P et al (2002) Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 161[Suppl 1]:S20–S34
Kuijpers TW, Maianski NA, Tool AT et al (2003) Apoptotic neutrophils in the circulation of patients with glycogen storage disease type 1b (GSD1b). Blood 101:5021–5024
Visser G, Rake JP, Fernandes J et al (2000) Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European Study on Glycogen Storage Disease type I. J Pediatr 137:187–191
Foster JD, Nordlie RC (2002) The biochemistry and molecular biology of the glucose-6-phosphatase system. Exp Biol Med (May-wood) 227:601–608
Waddell ID, Burchell A (1993) Identification, purification and genetic deficiencies of the glucose-6-phosphatase system transport proteins. Eur J Pediatr 152[Suppl 1]: S14–S17
Veiga-da-Cunha M, Gerin I, Chen YT et al (1999) The putative glucose 6-phosphate translocase gene is mutated in essentially all cases of glycogen storage disease type I non-a. Eur J Hum Genet 7: 717–723
Burchell A (1998) A reevaluation of GLUT 7. Biochem J 331:973
Melis D, Havelaar AC, Verbeek E et al (2004) NPT4, a new microsomal phosphate transporter: mutation analysis in glycogen storage disease type Ic. J Inherit Metab Dis 27: 725–733
Collins JE, Bartlett K, Leonard JV, Ayynsley-Green A (1990) Glucose production rates in type 1 glycogen storage disease. J Inherit Metab Dis 13:195–206
Fernandes J (1974) The effect of disaccharides on the hyperlactacidaemia of glucose-6-phosphatase-deficient children. Acta Paediatr Scand 63: 695–698
Fernandes J, Alaupovic P, Wit JM (1989) Gastric drip feeding in patients with glycogen storage disease type I: its effects on growth and plasma lipids and apolipoproteins. Pediatr Res 25: 327–331
Greene HL, Swift LL, Knapp HR (1991) Hyperlipidemia and fatty acid composition in patients treated for type IA glycogen storage disease. J Pediatr 119:398–403
Alaupovic P, Fernandes J (1985) The serum apolipoprotein profile of patients with glucose-6-phosphatase deficiency. Pediatr Res 19:380–384
Bandsma RH, Smit GP, Kuipers F (2002) Disturbed lipid metabolism in glycogen storage disease type 1. Eur J Pediatr 161[Suppl 1]:S65–S69
Fernandes J, Pikaar NA (1972) Ketosis in hepatic glycogenosis. Arch DisChild 47: 41–46
Greene HL, Wilson FA, Hefferan P et al (1978) ATP depletion, a possible role in the pathogenesis of hyperuricemia in glycogen storage disease type I. J Clin Invest 62:321–328
Cohen JL, Vinik A, Faller J, Fox IH (1985) Hyperuricemia in glycogen storage disease type I. Contributions by hypoglycemia and hyperglucagonemia to increased urate production. J Clin Invest 75: 251–257
Matern D, Seydewitz HH, Bali D, Lang C, Chen YT (2002) Glycogen storage disease type I: diagnosis and phenotype/genotype correlation. Eur J Pediatr 161[Suppl 1]: S10–S19
Rake JP, ten Berge AM, Visser G et al (2000) Glycogen storage disease type Ia: recent experience with mutation analysis, a summary of mutations reported in the literature and a newly developed diagnostic flow chart. Eur J Pediatr 159:322–330
Chou JY, Matern D, Mansfield BC, Chen YT (2002) Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex. Curr Mol Med 2:121–143
Lin B, Hiraiwa H, Pan CJ, Nordlie RC, Chou JY (1999) Type-1c glycogen storage disease is not caused by mutations in the glucose-6-phosphate transporter gene. Hum Genet 105:515–517
Narisawa K, Otomo H, Igarashi Y et al (1983) Glycogen storage disease type 1b: microsomal glucose-6-phosphatase system in two patients with different clinical findings. Pediatr Res 17:545–549
Burr IM, O’Neill JA, Karzon DT, Howard LJ, Greene HL (1974) Comparison of the effects of total parenteral nutrition, continuous intragastric feeding, and portacaval shunt on a patient with type I glycogen storage disease. J Pediatr 85:792–795
Chen YT, Cornblath M, Sidbury JB (1984) Cornstarch therapy in type I glycogen-storage disease. N Engl J Med 310:171–175
Wolfsdorf JI, Crigler JF, Jr (1999) Effect of continuous glucose therapy begun in infancy on the long-term clinical course of patients with type I glycogen storage disease. J Pediatr Gastroenterol Nutr 29:136–143
Smit GP, Ververs MT, Belderok B, Van Rijn M, Berger R, Fernandes J (1988) Complex carbohydrates in the dietary management of patients with glycogenosis caused by glucose-6-phosphatase deficiency. Am J Clin Nutr 48:95–97
Wolfsdorf JI, Keller RJ, Landy H, Crigler JF, Jr (1990) Glucose therapy for glycogenosis type 1 in infants: comparison of intermittent uncooked cornstarch and continuous overnight glucose feedings. J Pediatr 117:384–391
Fernandes J, Berger R, Smit GP (1984) Lactate as a cerebral metabolic fuel for glucose-6-phosphatase deficient children. Pediatr Res 18:335–339
Daublin G, Schwahn B, Wendel U (2002) Type I glycogen storage disease: favourable outcome on a strict management regimen avoiding increased lactate production during childhood and adolescence. Eur J Pediatr 161[Suppl 1]:S40–S45
Weinstein DA., Somers MJ, Wolfsdorf JI (2001) Decreased urinary citrate excretion in type 1a glycogen storage disease. J Pediatr 138:378–382
Wittenstein B, Klein M, Finckh B, Ullrich K, Kohlschutter A (2002) Radical trapping in glycogen storage disease 1a. Eur J Pediatr 161[Suppl 1]:S70–S74
Bandsma RH, Rake JP, Visser G et al (2002) Increased lipogenesis and resistance of lipoproteins to oxidative modification in two patients with glycogen storage disease type 1a. J Pediatr 140:256–260
Mairovitz V, Labrune P, Fernandez H, Audibert F, Frydman R (2002) Contraception and pregnancy in women affected by glycogen storage diseases. Eur J Pediatr 161[Suppl 1]:S97–101
Kerr KG (1999) The prophylaxis of bacterial infections in neutropenic patients. J Antimicrob Chemother 44:587–591
Visser G, Rake JP, Labrune P et al (2002) Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 161[Suppl 1]:S83–S87
Visser G, Rake JP, Labrune P et al (2002) Consensus guidelines for management of glycogen storage disease type 1b-European Study on Glycogen Storage Disease Type 1. Eur J Pediatr 161[Suppl 1]:S120–S123
Simmons PS, Smithson WA, Gronert GA, Haymond MW (1984) Acute myelogenous leukemia and malignant hyperthermia in a patient with type 1b glycogen storage disease. J Pediatr 105: 428–431
Donadieu J, Barkaoui M, Bezard F, Bertrand Y, Pondarre C, Guiband P (2000) Renal carcinoma in a patient with glycogen storage disease Ib receiving long-term granulocyte colony-stimulating factor therapy. J Pediatr Hematol Oncol 22:188–189
Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP (2002) Guidelines for management of glycogen storage disease type I-European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr 161[Suppl 1]:S112–S119
Hagen T, Korson MS, Wolfsdorf JI (2000) Urinary lactate excretion to monitor the efficacy of treatment of type I glycogen storage disease. Mol Genet Metab 70:189–195
Lee PJ, Chatterton C, Leonard JV (1996) Urinary lactate excretion in type 1 glycogenosis—a marker of metabolic control or renal tubular dysfunction? J Inherit Metab Dis 19:201–204
Visser G, Rake JP, Kokke FT, Nikkels PG, Sauer PJ, Smit GP (2002) Intestinal function in glycogen storage disease type I. J Inherit Metab Dis 25:261–267
Talente GM, Coleman RA, Alter C et al (1994) Glycogen storage disease in adults. Ann Intern Med 120:218–226
Chen YT (1991) Type I glycogen storage disease: kidney involvement, pathogenesis and its treatment. Pediatr Nephrol 5:71–76
Lee PJ, Dalton RN, Shah V, Hindmarsh PC, Leonard JV (1995) Glomerular and tubular function in glycogen storage disease. Pediatr Nephrol 9:705–710
Chen YT, Scheinman JI, Park HK, Coleman RA, Roe CR (1990) Amelioration of proximal renal tubular dysfunction in type I glycogen storage disease with dietary therapy. N Engl J Med 323:590–593
Iida S, Matsuoka K, Inouse M, Tomiyasu K, Noda S (2003) Calcium nephrolithiasis and distal tubular acidosis in type 1 glycogen storage disease. Int J Urol 10:56–58
Restaino I, Kaplan BS, Stanley C, Baker L (1993) Nephrolithiasis, hypocitraturia, and a distal renal tubular acidification defect in type 1 glycogen storage disease. J Pediatr 122:392–396
Baker L, Dahlem S, Goldfarb S et al (1989) Hyperfiltration and renal disease in glycogen storage disease, type I. Kidney Int 35:1345–1350
Chen YT, Coleman RA, Scheinman JI, Kolbeck PC, Sidbury JB (1988) Renal disease in type I glycogen storage disease. N Engl J Med 318:7–11
Labrune P, Trioche P, Duvaltier I, Chevalier P, Odievre M (1997) Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 24:276–279
Lee PJ (2002) Glycogen storage disease type I: pathophysiology of liver adenomas. Eur J Pediatr 161[Suppl 1]: S46–S49
Bianchi L (1993) Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 152[Suppl 1]:S63–S70
Labrune P (2002) Glycogen storage disease type I: indications for liver and/or kidney transplantation. Eur J Pediatr 161[Suppl 1]:S53–S55
Matern D, Starzl TE, Arnaout W et al (1999) Liver transplantation for glycogen storage disease types I, III, and IV. Eur J Pediatr 158[Suppl 2]:S43–S48
Lee PJ, Patel JS, Fewtrell M, Leonard JV, Bishop NJ (1995) Bone mineralisation in type 1 glycogen storage disease. Eur J Pediatr 154:483–487
Rake JP, Visser G, Huismans D et al (2003) Bone mineral density in children, adolescents and adults with glycogen storage disease type Ia: a cross-sectional and longitudinal study. J Inherit.Metab Dis 26:371–384
Weinstein DA, Roy CN, Fleming MD, Loda MF, Wolfsdorf JI, Andrews NC (2002) Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 100:3776–3781
Lee PJ, Patel A, Hindmarsh PC, Mowat AP, Leonard JV (1995) The prevalence of polycystic ovaries in the hepatic glycogen storage diseases: its association with hyper insulinism. Clin Endocrinol (Oxf) 42:601–606
Lee PJ, Celermajer DS, Robinson J, McCarthy SN, Betteridge DJ, Leonard JV (1994) Hyperlipidaemia does not impair vascular endothelial function in glycogen storage disease type 1a. Atherosclerosis 110:95–100
Corby DG, Putnam CW, Greene HL (1974) Impaired platelet function in glucose-6-phosphatase deficiency. J Pediatr 85:71–76
Trioche P, Francoual J, Capel L, Odievre M, Lindenbaum A, Labrune P (2000) Apolipoprotein E polymorphism and serum concentrations in patients with glycogen storage disease type Ia. J Inherit Metab Dis 23:107–112
Humbert M, Labrune P, Simonneau G (2002) Severe pulmonary arterial hypertension in type 1 glycogen storage disease. Eur J Pediatr 161[Suppl 1]: S93–S96
DiMauro S, Hartwig GB, Hays A et al (1979) Debrancher deficiency: neuromuscular disorder in 5 adults. Ann Neurol 5:422–436
DiMauro S, Hays AP, Tsujino S (2004) Nonlysosomal glycogenosis. In: Engel AG, Franzini-Amstrong C (eds) Myology: basic and clinical. McGraw-Hill, New York, pp 1535–1558
Wolfsdorf JI, Weinstein DA (2003) Glycogen storage diseases. Rev Endocrinol Metab Disord 4:95–102
Lucchiari S, Fogh I, Prelle A et al (2002) Clinical and genetic variability in glycogen storage disease type IIIa: Seven novel AGL gene mutations in the Mediterranean area. Am J Med Genet 109:183–190
Lee P (1999) Successful pregnancy in a patient with type III glycogen storage disease managed with cornstarch supplements. Br J Obstet Gyneacol 106:181–182
de Moor RA, Schweizer JJ, van Hoek B, Wasser M, Vink R, Maaswinkel-Mooy PD (2000) Hepatocellular carcinoma in glycogen storage disease type IV. Arch Dis Child 82:479–480
Moses SW, Parvari R (2002) The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies. Curr Mol Med 2:177–188
Selby R, Starzl TE, Yunis E et al (1993) Liver transplantation for type I and type IV glycogen storage disease. Eur J Pediatr 152[Suppl 1]: S71–S76
Lossos A, Meiner Z, Barash V et al (1998) Adult polyglucosan body disease in Ashkenazi Jewish patients carrying the Tyr329Ser mutation in the glycogen-branching enzyme gene. Ann Neurol 44:867–872
Tay SK, Akman HO, Chung WK et al (2004) Fatal infantile neuromuscular presentation of glycogen storage disease type IV. Neuromuscul Disord 14: 253–260
Bao Y, Kishnani P, Wu JY, Chen HT (1996) Hepatic and neuromuscular forms of glycogen storage disease type IV caused by mutations in the same glycogen-branching enzyme gene. J Clin Invest 97:941–948
Hendrickx J, Willems PJ (1996) Genetic deficiencies of the glycogen phosphorylase system. Hum Genet 97:551–556
Huijing F, Fernandes J (1969) X-chromosomal inheritance of liver glycogenosis with phosphorylase kinase deficiency. Am J Hum Genet 21:275–284
Arad M, Maron BJ, Gorham JM et al (2005) Glycogen storage disease presenting as hypertrophic cardiomyopathy. N Engl J Med 352:362–372
Fernandes J, Koster JF, Grose WF, Sorgedrager N (1974) Hepatic phosphorylase deficiency. Its differentiation from other hepatic glycogenoses. Arch Dis Child 49:186–191
Willems PJ, Gerver WJ, Berger R, Fernandes J (1990) The natural history of liver glycogenosis due to phosphorylase kinase deficiency: a longitudinal study of 41 patients. Eur J Pediatr 149:268–271
Hendrickx J, Dams E, Coucke P, Lee P, Fernandes J, Willems PJ (1996) X-linked liver glycogenosis type II (XLG II) is caused by mutations in PHKA2, the gene encoding the liver alpha subunit of phosphorylase kinase. Hum Mol Genet 5:649–652
Hendrickx J, Lee P, Keating JP et al (1999) Complete genomic structure and mutational spectrum of PHKA2 in patients with x-linked liver glycogenosis type I and II. Am J Hum Genet 64:1541–1549
Bruno C, Manfredi G, Andreu AL et al (1998) A splice junction mutation in the alpha(M) gene of phosphorylase kinase in a patient with myopathy. Biochem Biophys Res Commun 249:648–651
Wehner M, Clemens PR, Engel AG, Kilimann MW (1994) Human muscle glycogenosis due to phosphorylase kinase deficiency associated with a nonsense mutation in the muscle isoform of the alpha subunit. Hum Mol Genet 3:1983–1987
Burwinkel B, Hu B, Schroers A et al (2003) Muscle glycogenosis with low phosphorylase kinase activity: mutations in PHKA1, PHKG1 or six other candidate genes explain only a minority of cases. Eur J Hum Genet 11:516–526
Schippers HM, Smit GP, Rake JP, Visser G (2003) Characteristic growth pattern in male X-linked phosphorylase-b kinase deficiency (GSD IX). J Inherit Metab Dis 26:43–47
Aynsley-Green A, Williamson DH, Gitzelmann R (1977) Hepatic glycogen synthetase deficiency. Definition of syndrome from metabolic and enzyme studies on a 9-year-old girl. Arch Dis Child 52:573–579
Laberge AM, Mitchell GA, van de Werve G, Lambert M (2003) Longterm follow-up of a new case of liver glycogen synthase deficiency. Am J Med Genet A 120:19–22
Orho M, Bosshard NU, Buist NR et al (1998) Mutations in the liver glycogen synthase gene in children with hypoglycemia due to glycogen storage disease type 0. J Clin Invest 102:507–515
Tonin P, Lewis PJ, Servidei S, DiMauro S (1990) Metabolic causes of myoglobinuria. Ann Neurol 27:181–185
Martin MA, Rubio JC, Wevers RA et al (2004) Molecular analysis of myophosphorylase deficiency in Dutch patients with McArdle’s disease. Ann Hum Genet 68:17–22
Bartram C, Edwards RH, Clague J, Beynon RJ (1993) McArdle’s disease: a nonsense mutation in exon 1 of the muscle glycogen phosphorylase gene explains some but not all cases. Hum Mol Genet 2:1291–1293
el Schahawi M, Tsujino S, Shanske S, DiMauro S (1996) Diagnosis of McArdle’s disease by molecular genetic analysis of blood. Neurology 47:579–580
Tsujino S, Shanske S, Carroll JE, Sabina RL, DiMauro S (1994) Two mutations, one novel and one frequently observed, in Japanese patients with McArdle’s disease. Hum Mol Genet 3:1005–1006
Martinuzzi A, Sartori E, Fanin M et al (2003) Phenotype modulators in myophosphorylase deficiency. Ann Neurol 53:497–502
Kazemi-Esfarjani P, Skomorowska E, Jensen TD, Haller RG, Vissing A (2002) A nonischemic forearm exercise test for McArdle disease. Ann Neurol 52:153–159
Vissin J, Haller RG (2003) A diagnostic cycle test for McArdle’s disease. Ann Neurol 54:539–542
Haller RG (2000) Treatment of McArdle disease. Arch Neurol 57:923–924
Vissing J, Haller RG (2003) The effect of oral sucrose on exercise tolerance in patients with McArdle’s disease. N Engl J Med 349: 2503–2509
Haller RG, Vissing J (2004) No spontaneous second wind in muscle phosphofructokinase deficiency. Neurology 62:82–86
Morimoto A, Ueda I, Hirashima Y et al (2003) A novel missense mutation (1060G → C) in the phosphoglycerate kinase gene in a Japanese boy with chronic haemolytic anaemia, developmental delay and rhabdomyolysis. Br J Haematol 122:1009–1013
Schroder JM, Dodel R, Weis J, Stefanidis I, Reichmann H (1996) Mitochondrial changes in muscle phosphoglycerate kinase deficiency. Clin Neuropathol 15:34–40
Vissing J, Schmalbruch H, Haller RG, Clausen T (1999) Muscle phosphoglycerate mutase deficiency with tubular aggregates: effect of dantrolene. Ann Neurol 46: 274–277
Kreuder J, Borkhardt A, Repp R et al (1996) Brief report: inherited metabolic myopathy and hemolysis due to a mutation in aldolase A. N Engl J Med 334:1100–1104
Comi GP, Fortunato F, Lucchiari S et al (2001) Beta-enolase deficiency, a new metabolic myopathy of distal glycolysis. Ann Neurol 50:202–207
Kanno T, Maekawa M (1995) Lactate dehydrogenase M-subunit deficiencies: clinical features, metabolic background, and genetic heterogeneities. Muscle Nerve 3:S54–S60
Holme E, Kollberg G, Oldfors A et al (2005) Muscular glycogen storage disease 0 — A new disease entity in a child with hypertrophic cardiomyopathy and myopathy due to a homozygous stop mutation in the muscular glycogen synthase gene (GYS1). J Inherit Metab Dis 28[Suppl 1]:214
Van den Hout HM, Hop W, van Diggelen OP et al (2003) The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112:332–340
Makos MM, McComb RD, Hart MN, Bennett DR (1987) Alpha-glucosidase deficiency and basilar artery aneurysm: report of a sibship. Ann Neurol 22:629–633
Hagemans ML, Janssens AC, Winkel LP et al (2004) Late-onset Pompe disease primarily affects quality of life in physical health domains. Neurology 63:1688–1692
Van den Hout JM, Kamphoven JH, Winkel LP et al (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113:e448–e457
Winkel LP, Van den Hout JM, Kamphoven JH et al (2004) Enzyme replacement therapy in late-onset Pompe’s disease: a three-year follow-up. Ann Neurol 55:495–502
Danon MJ, Oh SJ, DiMauro S et al (1981) Lysosomal glycogen storage disease with normal acid maltase. Neurology 31:51–57
Nishino I, Fu J, Tanji K et al (2000) Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature 406:906–910
Dworzak F, Casazza F, Mora M et al (1994) Lysosomal glycogen storage with normal acid maltase: a familial study with successful heart transplant. Neuromuscul Disord 4:243–247
Minassian BA, Ianzano L, Meloche M et al (2000) Mutation spectrum and predicted function of laforin in Lafora’s progressive myoclonus epilepsy. Neurology 55:341–346
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Smit, G.P.A., Rake, J.P., Akman, H.O., DiMauro, S. (2006). The Glycogen Storage Diseases and Related Disorders. In: Fernandes, J., Saudubray, JM., van den Berghe, G., Walter, J.H. (eds) Inborn Metabolic Diseases. Springer, Berlin, Heidelberg . https://doi.org/10.1007/978-3-540-28785-8_6
Download citation
DOI: https://doi.org/10.1007/978-3-540-28785-8_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-28783-4
Online ISBN: 978-3-540-28785-8
eBook Packages: MedicineMedicine (R0)